# Fruquintinib Combined With Sintilimab ± Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver Metastases

> **NCT06356584** · PHASE2 · RECRUITING · sponsor: **Shandong Cancer Hospital and Institute** · enrollment: 62 (estimated)

## Conditions studied

- Colorectal Cancer
- Immunotherapy
- Radiotherapy
- Targeted Therapy
- Liver Metastasis

## Interventions

- **DRUG:** Immunotherapy (Sintilimab)
- **DRUG:** Targeted Therapy Agent (Fruquintinib)
- **RADIATION:** Radiotherapy (SBRT and LDRT)

## Key facts

- **NCT ID:** NCT06356584
- **Lead sponsor:** Shandong Cancer Hospital and Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-01
- **Primary completion:** 2026-10-01
- **Final completion:** 2026-10-01
- **Target enrollment:** 62 (ESTIMATED)
- **Last updated:** 2026-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06356584

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06356584, "Fruquintinib Combined With Sintilimab ± Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver Metastases". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06356584. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*